Labcorp (LH) Projected to Post Quarterly Earnings on Tuesday

Labcorp (NYSE:LH) will likely be posting its Q4 2025 results before the market opens on Tuesday, February 17th. Analysts expect Labcorp to post earnings of $3.95 per share and revenue of $3.5597 billion for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 17, 2026 at 9:00 AM ET.

Labcorp Trading Up 1.6%

LH stock opened at $282.64 on Monday. Labcorp has a 12-month low of $209.38 and a 12-month high of $293.72. The business’s 50-day moving average is $263.59 and its 200 day moving average is $268.65. The company has a current ratio of 1.55, a quick ratio of 1.35 and a debt-to-equity ratio of 0.59. The stock has a market cap of $23.43 billion, a price-to-earnings ratio of 27.76, a PEG ratio of 1.78 and a beta of 1.03.

Labcorp Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 12th. Investors of record on Friday, February 27th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Friday, February 27th. Labcorp’s payout ratio is presently 28.29%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on LH shares. UBS Group decreased their price objective on Labcorp from $325.00 to $320.00 and set a “buy” rating on the stock in a report on Wednesday, October 29th. Wall Street Zen upgraded shares of Labcorp from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Weiss Ratings upgraded shares of Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, February 10th. Robert W. Baird set a $313.00 price objective on shares of Labcorp in a report on Wednesday, January 14th. Finally, JPMorgan Chase & Co. raised their target price on shares of Labcorp from $317.00 to $319.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. Ten equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Labcorp presently has a consensus rating of “Moderate Buy” and a consensus target price of $300.75.

Insider Activity at Labcorp

In other Labcorp news, CEO Adam H. Schechter sold 5,273 shares of the firm’s stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $284.38, for a total transaction of $1,499,535.74. Following the completion of the sale, the chief executive officer owned 87,343 shares of the company’s stock, valued at $24,838,602.34. This trade represents a 5.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jonathan C. Meltzer sold 87 shares of Labcorp stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $290.42, for a total value of $25,266.54. Following the completion of the sale, the executive vice president owned 2,782 shares in the company, valued at $807,948.44. This represents a 3.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.84% of the company’s stock.

Hedge Funds Weigh In On Labcorp

Several hedge funds have recently bought and sold shares of LH. JPL Wealth Management LLC acquired a new position in Labcorp in the 3rd quarter valued at about $28,000. Headlands Technologies LLC boosted its stake in shares of Labcorp by 300.0% in the second quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 96 shares during the period. Caitong International Asset Management Co. Ltd boosted its stake in shares of Labcorp by 575.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 162 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 138 shares during the period. Larson Financial Group LLC grew its holdings in shares of Labcorp by 37.5% in the third quarter. Larson Financial Group LLC now owns 154 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 42 shares in the last quarter. Finally, MUFG Securities EMEA plc purchased a new stake in Labcorp during the 2nd quarter worth approximately $65,000. Institutional investors and hedge funds own 95.94% of the company’s stock.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.